Jeffrey David Jacobson
Known title: Chief Growth OfficerCIK: 0001796124
Associated companies
Transaction History
| CRON | ▲ Buy | Option Exercise | 59,191 | $0 | 3/15/2026 | View on chart |
| CRON | ▼ Sell | Tax Withholding | 22,552 | $56K | 3/15/2026 | View on chart |
| CRON | ▲ Buy | Option Exercise | 65,179 | $0 | 3/12/2026 | View on chart |
| CRON | ▼ Sell | Tax Withholding | 24,926 | $64K | 3/12/2026 | View on chart |
| CRON | ▲ Buy | Option Exercise | 60,536 | $0 | 3/8/2026 | View on chart |
| CRON | ▼ Sell | Tax Withholding | 25,605 | $66K | 3/8/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Cronos completes acquisition of CanAdelaar, expands European presence
Cronos Group announced the completion of its acquisition of CanAdelaar, the largest adult‑use cannabis company in Europe. The deal adds a significant European footprint to Cronos’ operations and may enhance its product distribution across the region. Around the same time, Zuanic & Associates initiated coverage of Cronos with an Overweight rating, indicating a favorable view from the analyst. The stock is currently trading near its $2.72 support level with a mid‑range RSI, suggesting modest momentum.
Cronos completes acquisition of CanAdelaar, expands European presence. Cronos Group announced the completion of its acquisition of CanAdelaar, the largest adult‑use cannabis company in Europe. The deal adds a significant European footprint to Cronos’ operations and may enhance its product distribution across the region. Around the same time, Zuanic & Associates initiated coverage of Cronos with an Overweight rating, indicating a favorable view from the analyst. The stock is currently trading near its $2.72 support level with a mid‑range RSI, suggesting modest momentum.